Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.
Solid Tumors
DRUG: ABT-263|DRUG: paclitaxel
Safety Assessment, Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule of ABT-263 in combination with Paclitaxel, Weekly|Efficacy Assessment, Evaluate preliminary data regarding objective response rate (ORR), progression free survival (PFS), time to tumor progression (TTP), overall survival (OS), duration of overall response, and, ECOG performance status, Bi-monthly
A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination with Paclitaxel in the Treatment of Subjects with Solid Tumors.